Role of Toxoplasma mitochondrial respiration and ATP synthesis in parasite survival, virulence, and persistence – a complex story! (360G-Wellcome-310879_Z_24_Z)

£3,300,451

Apicomplexan parasites cause severe diseases, including toxoplasmosis and malaria. Toxoplasmosis can be fatal in immunocompromised patients and persists for life. Drug resistance and side effects necessitate new drugs. The apicomplexan mitochondrial electron transport chain (mETC) and ATP synthase pathway offers excellent opportunities to develop better drugs, because this pathway is critical for parasite survival and virulence and has striking differences from the human pathway. We recently found that each of the parasite enzymes consists of different subunits and show structural differences from their human parallels(1–3), manifesting in selective sensitivity to inhibitors, e.g the clinically used atovaquone. Yet, the function of the new subunits and how these differences lead to increased drug sensitivity in the parasite are not understood, hindering the development of better drugs. Moreover, some new subunits are essential for virulence in animals, and mETC inhibitors further kill bradyzoites, the persistent life- stage. Yet the pathway’s role during animal infection and bradyzoites biology remain largely understudied. This work will generate mechanistic understanding of divergent aspects of apicomplexan mETC and ATP synthase, reveal their role during animal infection, and develop studies of their role during persistence. We will further elicit inhibitor mode-of-action, together informing drug development for toxoplasmosis and potentially malaria.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Region Scotland
Award Date 2024-09-17T00:00:00+00:00
Internal ID 310879/Z/24/Z
Planned Dates: End Date 2032-12-10T00:00:00+00:00
Planned Dates: Start Date 2024-12-11T00:00:00+00:00
Amount Awarded 3300451
Financial Year 2023/24
Lead Applicant Prof Lilach Sheiner
Grant Programme: Title Discovery Award
Applicant Surname Sheiner
Approval Committee DSV Interview Committee
Other Applicant(s) Dr Alexander Mühleip, Dr Anita Koshy
Recipient Org: Country United Kingdom
Recipient Org: City Glasgow
Has the grant transferred? No
Research conducted at multiple locations? No
Total amount including partnership funding 3300451

Help shape the next 10 years of GrantNav!

GrantNav is celebrating its 10th anniversary. Take our quick 3-minute survey to tell us how we can make the data work better for you.

Take the Survey